1. Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents J Am Coll Cardiol. 2016;68(1):92-125. doi:10.1016/j.jacc.2016.03.519 Figure Legend: Patient Populations Addressed and Factors and Interventions to Consider

2. Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents J Am Coll Cardiol. 2016;68(1):92-125. doi:10.1016/j.jacc.2016.03.519 Figure Legend: Patients ≥21 Years of Age with Stable Clinical ASCVD without Comorbidities, on Statin for Secondary Prevention

3. Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents J Am Coll Cardiol. 2016;68(1):92-125. doi:10.1016/j.jacc.2016.03.519 Figure Legend: Patients ≥21 Years of Age with Clinical ASCVD with Comorbidities, on Statin for Secondary Prevention

4. Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents J Am Coll Cardiol. 2016;68(1):92-125. doi:10.1016/j.jacc.2016.03.519 Figure Legend: Patients ≥21 Years of Age with Clinical ASCVD and Baseline LDL-C ≥190 mg/dL Not Due to Secondary Causes, on Statin for Secondary Prevention

5. Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents J Am Coll Cardiol. 2016;68(1):92-125. doi:10.1016/j.jacc.2016.03.519 Figure Legend: Patients ≥21 Years of Age without Clinical ASCVD and with Baseline LDL-C ≥190 mg/dL Not Due to Secondary Causes, on Statin for Primary Prevention

6. Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents J Am Coll Cardiol. 2016;68(1):92-125. doi:10.1016/j.jacc.2016.03.519 Figure Legend: Patients Aged 40-75 years without Clinical ASCVD and with Diabetes and Baseline LDL-C 70-189 mg/dL, on Statin for Primary Prevention

7. Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents J Am Coll Cardiol. 2016;68(1):92-125. doi:10.1016/j.jacc.2016.03.519 Figure Legend: Patients Aged 40-75 years without Clinical ASCVD or Diabetes, with LDL-C 70-189 mg/dL and 10-Year ASCVD Risk ≥7.5%, on Statin for Primary Prevention